| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | OSI-027 | CTRPv2 | pan-cancer | AAC | -0.04 | 0.2 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.064 | 0.2 |
| mRNA | GSK429286A | GDSC1000 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | KU-0063794 | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | -0.056 | 0.3 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | -0.046 | 0.3 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | JNJ-26854165 | GDSC1000 | pan-cancer | AAC | 0.038 | 0.3 |